Publications by authors named "Evanka Annyapu"
Objective: Despite widespread use, there is limited evidence to support postsurgical rehabilitation to enhance neurological recovery after surgery for degenerative cervical myelopathy (DCM). Outcomes research for DCM seldom accounts for the effect of postsurgical rehabilitation. The aim of this study was to quantify the impact of postsurgical rehabilitation on outcomes after surgery for DCM.
View Article and Find Full Text PDFPersistent Immune Effector Cell Associated Hematotoxicity (ICAHT) is a significant side effect of BCMA CAR T-Cell therapy in patients with relapsed multiple myeloma (MM). The use of stem cell boosts in ICAHT has been described, however studies have been limited by small patient numbers and short follow up. Herein, we report on our multi-institutional experience of ICAHT, defined by an absolute neutrophil count (ANC) of ≤ 1000, thrombocytopenia with a platelet count ≤ 50,000 or/and anemia as hemoglobin (hgb) ≤9 g/dL, in patients who received BCMA CAR T therapy, and the effects of subsequent stem cell boost on hematopoietic reconstitution and clinical outcome.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates infection risks associated with two types of bispecific antibodies (bsAb)—BCMA and GPRC5D—in patients with relapsed/refractory multiple myeloma (RRMM), focusing on incidence and risk factors for infections during and after treatment.
- Results show that BCMA bsAb therapy had a higher infection rate and a greater proportion of severe infections (grade ≥3) compared to GPRC5D treatment, with 58% of infections in the BCMA group classified as severe.
- The findings suggest that patients receiving BCMA bsAb and GPRC5D combination therapies have a greater cumulative incidence of overall and severe infections compared to those receiving GPRC5D monotherapy.